OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Headache and Pain is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine	473
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition	234
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis	149
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II	108
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	103
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study	101
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency	87
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	82
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	73
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	67
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study	63
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials	59
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	57
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan	57
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache	55
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study	54
Characteristics of N400 component elicited in patients who have migraine with aura	51
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks	49
Measuring interictal burden among people affected by migraine: a descriptive survey study	48
Debate: Are cluster headache and migraine distinct headache disorders?	48
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke	47
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	46
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia	45
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	45
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	43

Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome	42
Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary	41
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine	40
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey	39
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China	39
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States	37
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial	36
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI	36
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study	35
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results	34
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury	34
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN	33
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting	32
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials	32
Attenuated alpha oscillation and hyperresponsiveness reveals impaired perceptual learning in migraineurs	32
Correction to: Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic revi	32
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study	32
Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea	31
Inflammatory complications of CGRP monoclonal antibodies: a case series	30
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany	29
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension	29
Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine	28
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas	28
Activation of CamKIIα expressing neurons on ventrolateral periaqueductal gray improves behavioral hypersensitivity and thalamic discharge in a trigeminal neuralgia rat model	28
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study	28
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study	27
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain	27
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance	26
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments	26
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana	26
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism	26
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study	26
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model	26
Development and validation of a novel model for characterizing migraine outcomes within real-world data	25
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients	25
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy	25
Age-related differences in resting state functional connectivity in pediatric migraine	24
Tracking the evolution of non-headache symptoms through the migraine attack	24
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report	24
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials	24
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study	24
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice	24
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study	24
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials	23
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients	23
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients	23
Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank	23
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-2019	23
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies	23
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study	23

Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study	23
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience	22
Contribution of tetrodotoxin-resistant persistent Na+ currents to the excitability of C-type dural afferent neurons in rats	22
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology	22
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis	22
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental ch	21
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)	21
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure	21
Genome-wide analysis identified novel susceptible genes of restless legs syndrome in migraineurs	21
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study	21
Prenatal oestrogen-testosterone balance as a risk factor of migraine in adults	21
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review	21
Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients	21
Functional connectivity of the visual cortex differentiates anxiety comorbidity from episodic migraineurs without aura	20
Insulin sensitizes neural and vascular TRPV1 receptors in the trigeminovascular system	20
Effects of a history of headache and migraine treatment on baseline neurocognitive function in young athletes	20
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study	20
Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine	20
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation	20
Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients	20
The patients’ perspective on the burden of idiopathic intracranial hypertension	20
Correction: Applying a biopsychosocial model to migraine: rationale and clinical implications	20
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients	19
Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period	19
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts	19
Long COVID headache	19
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 rece	19
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury	19
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab	19
Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation	19
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment i	18
Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey	18
Altered speech patterns in subjects with post-traumatic headache due to mild traumatic brain injury	18
Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists	18
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience	18
Post-traumatic trigeminal neuropathy: correlation between objective and subjective assessments and a prediction model for neurosensory recovery	18
Enhanced functional connectivity between habenula and salience network in medication-overuse headache complicating chronic migraine positions it within the addiction disorders: an ICA-based resting-st	18
Interictal osmophobia is associated with longer migraine disease duration	18
Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan	17
Long term evaluation of a multidisciplinary trigeminal neuralgia service	17
Is there a causal relationship between stress and migraine? Current evidence and implications for management	17
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results	17
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update	17
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension	17
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database	17
Functional correlation of ATP1A2 mutations with phenotypic spectrum: from pure hemiplegic migraine to its variant forms	17
The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study	17
The economic and personal burden of cluster headache: a controlled cross-sectional study	17
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis	17
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study	17
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study	16
Migraine and neuroinflammation: the inflammasome perspective	16
Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury	16
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	16
CGRP outflow into jugular blood and cerebrospinal fluid and permeance for CGRP of rat dura mater	16
Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup	16
Mild traumatic brain injury affects the features of migraine	16
Regional cerebral blood flow as predictor of response to occipital nerve block in cluster headache	16
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms	16
Cortical spreading depression can be triggered by sensory stimulation in primed wild type mouse brain: a mechanistic insight to migraine aura generation	15
The International Headache Congress – IHS and EHF joint congress 2021	15
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine	15
The impact of COVID-19 pandemic on headache symptoms and drug withdrawal among patients with medication overuse headache: a cross-sectional study	15
The relationship between headache-attributed disability and lost productivity: 1. A review of the literature	15
CACNA1A-p.Thr501Met mutation associated with familial hemiplegic migraine: a family report	15
The prevalence and burden of recurrent headache in Australian adolescents: findings from the longitudinal study of Australian children	15
Thalamo-cortical networks in subtypes of migraine with aura patients	15
The Global Campaign turns 18: a brief review of its activities and achievements	15
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)	14
Comment regarding: what is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta‑analysis of clinical trials	14
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine	14
A universal outcome measure for headache treatments, care-delivery systems and economic analysis	14
The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence	14
TIME, to move forward? comment on “a universal outcome measure for headache treatments, care-delivery systems and economic analysis”	14
Correction to: Hyperbaric oxygen attenuates neuropathic pain and reverses inflammatory signaling likely via the Kindlin-1/Wnt-10a signaling pathway in the chronic pain injury model in rats	14
A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine	14
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs	14